meta
|
evidence
oncology
Living systematic review and meta-analysis
endometrial cancer - (neo)adjuvant (NA)
1
esophageal cancer (EC)
immune chekpoint inhibitors
anti-PD-(L)1
camrelizumab based treatment
camrelizumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC
Tislelizumab
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
no study with result for this clinical condition